pH- and thermosensitive thin lipid layer coated mesoporous magnetic nanoassemblies as a dual drug delivery system towards thermochemotherapy of cancer
Source abstract
Abstract
A new pH-sensitive and thermosensitive dual drug delivery system consisting of thin lipid layer encapsulated mesoporous magnetite nanoassemblies (MMNA) has been developed which can deliver two anticancer drugs simultaneously. The formulation of lipid layer used is 5:2:2:2 w/w, DPPC:cholesterol:DSPE-PEG2000:MMNA. The structure, morphology and magnetic properties of MMNA and lipid coated MMNA (LMMNA) were thoroughly characterized. This hybrid system was investigated for its ability to carry two anticancer drugs as well as its ability to provide heat under an alternating current magnetic field (ACMF). A very high loading efficiency of up to ∼81% of doxorubicin hydrochloride (DOX) with an ∼0.02 mg mg(-1) loading capacity and ∼60% of paclitaxel (TXL) with an ∼0.03 mg mg(-1) loading capacity are obtained with LMMNA. A sustained release of drug is observed over a period of 172 h, with better release, of ∼88:53% (DOX:TXL), at pH 4.3 compared to the ∼28:26% (DOX:TXL) in physiological conditions (pH 7.4). An enhanced release of ∼72 and ∼68% is recorded for DOX and TXL, respectively, during the first hour with the application of an ACMF (∼43°C). A greater in vitro cytotoxic effect is observed with the two drugs compared to them individually in HeLa, MCF-7 and HepG2 cancer cells. With the application of an ACMF for 10 min, the cell killing efficiency is improved substantially due to simultaneous thermo- and chemotherapy. Confocal microscopy confirms the internalization of drug loaded MMNA and LMMNA by cells and their morphological changes during thermochemotherapy.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Characterization and Applications of Magnetic Nanoparticles · Nanopore and Nanochannel Transport Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (54)
Show source-provided references
1. Co- delivery of hydrophobic and hydrophilic drugs from nanoparticle–aptamer bioconjugates10.1002/cmdc.200700121 ↗
2. Monodisperse mesoporous superparamagnetic single-crystal magnetite nanoparticles for drug delivery10.1016/j.biomaterials.2008.12.042 ↗
3. Mesoporous biocompatible and acid-degradable magnetic colloidal nanocrystal clusters with sustainable stability and high hydrophobic drug loading capacity10.1021/nn103213y ↗
4. The targeted delivery of multicomponent cargos to cancer cells via nanoporous particle-supported lipid bilayers10.1038/nmat2992 ↗
5. In vitro application of paclitaxel loaded magnetoliposomes for combined chemotherapy and hyperthermia10.1016/j.colsurfb.2012.02.029 ↗
6. Nanomedicine – challenge and perspectives10.1002/anie.200802585 ↗
7. Nanotherapeutics to overcome conventional cancer chemotherapy limitations10.18433/J30C7D ↗
8. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties10.1016/S0163-7827(03)00033-X ↗
9. Effect of liposomecharacteristics and dose on the pharmacokinetics of liposomes coated with Poly(amino acid)s10.1007/s11095-007-9393-2 ↗
10. Dual drug release from electrospun poly(lactic-co-glycolic acid)/mesoporous silica nanoparticles composite mats with distinct release profiles10.1016/j.actbio.2012.01.020 ↗
11. Chitosan film containing poly(D, L-lactic-co -glycolic acid) nanoparticles: a platform for localized dual-drug release10.1007/s11095-010-0176-9 ↗
12. Biodegradable polymersomes loaded with both paclitaxel and doxorubicin permeate and shrink tumors, inducing apoptosis in proportion to accumulated drug10.1016/j.jconrel.2006.07.012 ↗
13. Combinatorial drug conjugation enables nanoparticle dual-drug delivery10.1002/smll.201000631 ↗
14. Composite polymeric magnetic nanoparticles for co-delivery of hydrophobic and hydrophilic anticancer drugs and MRI imaging for cancer therapy10.1021/am101196v ↗
15. Delivering hydrophilic and hydrophobic chemotherapeutics simultaneously by magnetic mesoporous silica nanoparticles to inhibit cancer cells
16. Mesoporous silica nanoparticle-based double drug delivery system for glucose-responsive controlled release of insulin and cyclic AMP10.1021/ja901831u ↗
17. Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma10.1002/cncr.24313 ↗
18. Synergistic inhibition of growth and induction of apoptosis by 8-chioro-cAMP and paditaxel or cisplatin in human cancer cells
19. Study of paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) administered every 2 weeks in patients with advanced solid tumors10.1159/000059568 ↗
20. Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic10.1093/oxfordjournals.annonc.a010717 ↗
21. Oxide and hybrid nanostructures for therapeutic applications10.1016/j.addr.2011.06.003 ↗
22. Nanoscale assembly of mesoporous ZnO: a potential drug carrier10.1039/c0jm00022a ↗
23. A multifunctional biphasic suspension of mesoporous silica encapsulated with YVO4:Eu3+ and Fe3O4 nanoparticles: synergistic effect towards cancer therapy and imaging10.1088/0957-4484/24/6/065101 ↗
24. Development of citrate-stabilized Fe3O4 nanoparticles: conjugation and release of doxorubicin for therapeutic applications10.1016/j.jmmm.2010.09.009 ↗
25. Photocytotoxicity and magnetic relaxivity responses of dual-porous γ-Fe2O3@meso-SiO2 microspheres10.1021/am300008x ↗
26. Novel synthesis of superparamagnetic magnetite nanoclusters for biomedical applications10.1039/c1jm11982f ↗
27. Synthesis of biocompatible, mesoporous Fe3O4 nano/microspheres with large surface area for magnetic resonance imaging and therapeutic applications10.1021/am1012358 ↗
28. Nanoscale assembly of amine functionalized colloidal iron oxide10.1016/j.jmmm.2009.02.080 ↗
29. Novel and efficient MR active aqueous colloidal Fe3O4 nanoassemblies10.1039/b911626e ↗
30. Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy10.1016/j.jconrel.2009.10.002 ↗
31. Physicochemical characterization and in vitroin vitro behavior of daunorubicin-loaded poly(butylcyanoacrylate) nanoparticles10.1016/j.actbio.2009.01.026 ↗
32. Yudina AS, de M, Coiffé ML, Langereis S, Ruijssevelt LV, Smirnov P, Bouchaud V, Voisin P, Grüll H, Moonen WCT. Ultrasound-mediated intracellular drug delivery using microbubbles and temperature-sensitive liposomes, J. Controlled Release 2011; 155: 442–448.10.1016/j.jconrel.2011.06.006 ↗
33. Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide10.1158/1535-7163.MCT-09-0045 ↗
34. The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles10.1016/j.biomaterials.2008.10.062 ↗
35. Induction heating studies of Fe3O4 magnetic nanoparticles capped with oleic acid and polyethylene glycol for hyperthermia10.1039/c1jm10092k ↗
36. Sulforhodamine B colorimetric assay for cytotoxicity screening10.1038/nprot.2006.179 ↗
37. Preparation of cells for assessing ultrastructural localization of nanoparticles with transmission electron microscopy10.1038/nprot.2010.2 ↗
38. Long-circulating and target-specific nanoparticles: theory to practice10.1016/S0031-6997(24)01494-7 ↗
39. Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging10.1016/j.addr.2009.11.002 ↗
40. Synthesis and characterizations of water-based ferro fluids of substituted ferrites [Fe1−xBxFe2O4, B=Mn, Co (x=0–1)] for biomedical applications10.1016/j.jmmm.2007.08.010 ↗
41. Magnetic nanomaterials for hyperthermia-based therapy and controlled drug delivery10.1016/j.addr.2011.03.008 ↗
42. Theory of magnetic fluid heating with an alternating magnetic field with temperature dependent materials properties for self-regulated heating10.1063/1.3076043 ↗
43. Size-sorted anionic iron oxide nanomagnets as colloidal mediators for magnetic hyperthermia10.1021/ja067457e ↗
44. Iron oxide monocrystalline nanoflowers for highly efficient magnetic hyperthermia10.1021/jp3025478 ↗
45. Porous nanoparticle supported lipid bilayers (Protocells) as delivery vehicles10.1021/ja808018y ↗
46. Magnetic mesoporous silica spheres for hyperthermia therapy10.1016/j.actbio.2010.06.030 ↗
47. Ferri-liposomes as an MRI-visible drug-delivery system for targeting tumours and their microenvironment10.1038/nnano.2011.112 ↗
48. The effects of pH and intraliposomal buffer strength on the rate of liposome content release and intracellular drug delivery10.1023/A:1020132226113 ↗
49. Hollow iron oxide nanoparticles as multidrug resistant drug delivery and imaging vehicles10.1007/s12274-012-0275-5 ↗
50. High-frequency, magnetic-field-responsive drug release from magnetic nanoparticle/organic hybrid based on hyperthermic effect10.1021/am100237p ↗
51. Noninvasive remote-controlled release of drug molecules in vitro using magnetic actuation of mechanized nanoparticles10.1021/ja1022267 ↗
52. Intracellular trafficking of superparamagnetic iron oxide nanoparticles conjugated with TAT peptide: 3-dimensional electron tomography analysis10.1016/j.bbrc.2012.04.080 ↗
53. Exchange-coupled magnetic nanoparticles for efficient heat induction10.1038/nnano.2011.95 ↗
54. PH-responsive peptide mimic shell cross-linked magnetic nanocarriers for combination therapy10.1002/adfm.201201140 ↗